The present invention is directed toward methods for treating and/or collecting information regarding neurological disorders, including language disorders, for example, aphasias.
A wide variety of mental and physical processes are controlled or influenced by neural activity in particular regions of the brain. For example, various physical or cognitive functions are directed or affected by neural activity within the various regions of the cerebral cortex. For most individuals, particular areas of the brain appear to have distinct functions. In the majority of people, for example, the areas of the occipital lobes relate to vision; the regions of the left inferior frontal lobes relate to language; portions of the cerebral cortex appear to be involved with conscious awareness, memory, and intellect; and particular regions of the cerebral cortex as well as the basal ganglia, the thalamus, and the motor cortex cooperatively interact to facilitate motor function control.
Aphasias are neurological disorders that affect the language centers of the brain. Aphasias are typically caused by brain lesions that result from a stroke or head injury. Different aphasias result from damage to different portions of the brain's language centers. For example, Broca's aphasia typically results from a large frontal lobe lesion and causes the patient to speak with great effort in a nonfluent manner, while generally not affecting the patient's comprehension of single words and simple sentences. Wernicke's aphasia typically results from damage to the left temporal lobe of the brain and impacts the patient's comprehension of words and sentences, usually without affecting the patient's fluency. Global aphasia can affect both Broca's area and Wernicke's area of the brain and can accordingly adversely affect both the patient's comprehension and speech fluency. Conduction aphasia is caused by damage to structures that interact with the major language areas of the brain. Conduction aphasia does not have as substantial an effect on the patient's comprehension or fluency as do other aphasias, but reduces the patient's ability to repeat sentences verbatim or easily name pictures and objects.
Practitioners have developed imaging techniques to isolate the portions of the brain affected by various aphasias. For example, Perani, et al. disclose identifying and tracking neurological functioning connected with language-based activities by obtaining functional magnetic resonance imaging (fMRI) data while the patient executes language-based tasks (see “A fMRI Study of Word Retrieval in Aphasia,” Brain and Language 85 (2003) pp. 357-368). Practitioners have also treated aphasia, for example, with conventional and/or melodic speech therapies, with drugs (e.g., amphetamines and other neuro-stimulatory agents) and with transcutaneous magnetic stimulation (TMS) applied to the brain. However, these techniques all suffer from drawbacks. In particular, the efficacies of speech therapy and drug-based techniques have not been conclusively demonstrated, and the effects of TMS are short-lived.
The following disclosure describes several methods for collecting information regarding neurological disorders, including language disorders, and methods for treating such disorders using electrical stimulation, for example, cortical stimulation. Cortical stimulation has been applied in other contexts, for example to enhance the recovery of cortical functions after a brain injury affecting motor capabilities. Several features of methods in accordance with embodiments of the invention are set forth and described in
In one particular aspect of this embodiment, the patient's language disorder can be entirely eliminated. In another particular aspect of this embodiment, the effects of the disorder can at least be diminished. In a further aspect of either embodiment, the stimulation site can be selected to be on the left side of the patient's brain, e.g., at or proximate to the language centers of the brain. In another aspect of these embodiments, the homologous structures on the right side of the patient's brain can be stimulated in addition to or in lieu of stimulating the left side of the patient's brain. Further details of the areas of the brain selected for stimulation, and the devices that apply the stimulation are discussed later with reference to
Referring next to
In one embodiment, process portion 112 can be carried out at least in part by a human operator, for example, a technician or physician who operates an imaging system. In another embodiment, the process of directing the collection of information can be performed partially or entirely by a computer, for example, by a hardware- and/or software-based routine that collects the information corresponding to the level of neural activity. In either embodiment, the information can take several forms and/or can correspond to the level of neural activity in the patient's brain by virtue of any of several techniques, as described below. As is also described below, a practitioner can direct the patient to perform one or more of a variety of language-based tasks that generate a neural response corresponding to the collected information.
In a particular aspect of an embodiment of the invention, the language-based task performed by the patient does not require the patient to actually vocalize. Instead, the patient can be directed to merely think of a word, letter, phrase or other language component. For example, the patient can be directed to silently generate a verb associated with a common noun, silently repeat a noun, silently retrieve a word based on a letter cue, or silently retrieve a word based on a visual cue. In particular cases, the patient can be directed to think of words beginning with the letter “C,” for example, or can be shown a picture of a cat and asked to think of the word represented by the picture. The patient can also be asked to respond nonverbally to an oral task that requires the patient to understand the difference between two auditory commands. In any of these embodiments, the patient need not use motor neurons to execute the selected task. An advantage of this arrangement is that reducing the number of motor neurons active while the patient performs the selected task can more clearly highlight those areas of the brain associated purely with the cognitive aspect of the language-based task. Put another way, this technique can reduce or eliminate the recorded activity of motor neurons, which might otherwise clutter or obscure the cognitive, language-based information of interest.
In other embodiments, the patient can be directed to perform any of the above tasks verbally. The practitioner can direct the patient to perform a verbal task when, for example, the motor activity associated with speech production will clearly not obscure neural responses associated with non-motor aspects of language-based tasks, and/or when it is desirable to locate and/or stimulate regions of the brain associated with motor aspects of the language-based tasks. In still further embodiments, the patient can be directed to perform a variety of language-based tasks and the information collected while the patient performs each task can be combined to aid the practitioner in determining a stimulation site. This technique can be used to identify multiple stimulation sites and/or to more definitively or precisely locate a particular stimulation site. In any of these embodiments, the methods described above include collecting information, such as imaging information, while the patient performs the task, as described in greater detail below.
The collected information can take the form of an image, generated using functional magnetic resonance imaging (fMRI) techniques, magnetic resonance imaging (MRI) techniques, computed tomography (CT) techniques, single photon emission computed tomography (SPECT) techniques, positron emission tomography (PET) techniques and/or other techniques. In any of these embodiments, a practitioner can view the image and, based at least in part on the image, identify a stimulation site for treating the language disorder. For example, the images can be color-coded or can have other distinguishing characteristics that allow the practitioner to distinguish active regions from inactive regions. In a particular embodiment, the active regions can be identified by a relatively elevated blood oxygen level, and in other embodiments, these regions can be identified on the basis of other characteristics.
In other embodiments, the foregoing techniques can be used to generate a digital representation of brain activity without necessarily generating a visible image. In a particular aspect of these embodiments, an algorithm or other computer-based method can be used to determine the stimulation site, based upon the digital representation described above. Whether or not the collected information is in the form of a visually accessible image, it can aid the practitioner in determining where to implant electrodes for applying electrical stimulation. The locations for the electrodes and the techniques for placing the electrodes at the stimulation sites are described in greater detail below with reference to
Methods in accordance with still further embodiments of the invention can include subsets of the method portions shown in
In one embodiment, the targeted areas of the brain 120 can include Broca's area 124 and/or Wernicke's area 125. In other embodiments, sections of the brain 120 anterior to, posterior to, or between these areas can be targeted in addition to or in lieu of targeting Broca's area 124 and Wernicke's area 125. For example, the targeted areas can include the middle frontal gyrus 121, the inferior frontal gyrus 122 and/or the inferior frontal lobe 123 anterior to Broca's area 124. In other embodiments, the areas targeted for stimulation can include the superior temporal lobe 127, the superior temporal gyrus 128, and/or the association fibers of the arcuate fasciculcus 126. In still further embodiments, the targeted areas can include the inferior parietal lobe 129 and/or other structures, including the supramarginal gyrus, angular gyrus, retrosplenial cortex and/or the retrosplenial cuneus of the brain 120.
One feature of an embodiment of the electrode assembly 140 described above with reference to
In another embodiment shown in
In other embodiments, the electrode assembly can have arrangements other than those described above. For example, other electrode assemblies can have support members with shapes other than those shown in
In one aspect of embodiments described above with reference to
In one aspect of this embodiment, the stimulation applied to the right side 120b of the patient's brain 120 can recruit right-side neurons to take over functions normally provided by (now defective) tissue on the left side 120a of the patient's brain 120. In another embodiment, (used, for example, when it is determined that recruiting homologous right-side neurons is actually detrimental to the patient's recovery of language-based functionality), the stimulation is applied to the right side 120b of the patient's brain 120 to impede or inhibit the body's attempts to recruit right-side neurons. In a particular aspect of this embodiment, the manner in which this stimulation is applied (e.g., the level of the voltage or current applied and/or the manner in which the voltage or current is varied or modulated) can determine whether the effect of the right-side neurons is enhanced or inhibited. In another embodiment, the location of the electrodes can determine whether the effect of the right-side neurons is enhanced or inhibited. In either embodiment, it can be advantageous to have a plurality of electrodes 542 (as shown in
In another aspect of an embodiment shown in
In one embodiment, the electrical signals can be applied to a single one of the electrodes 542 to provide a monopolar pulse of current to a small area of the brain 120. Accordingly, the system 650 can include a return electrode, which can be a portion of a pulse generator 651, or a separate electrode implanted elsewhere in the patient P (e.g., on the other side of the patient's brain 120 or at a subclavicular location). In other embodiments, electrical current can be passed through all of the electrodes 542 or only a subset of the electrodes 542 to activate larger or different populations of neurons. In one aspect of these embodiments, the potential applied to the electrodes 542 can be the same across all of the activated electrodes 542 to provide monopolar stimulation at the stimulation site. In other embodiments, some of the electrodes 542 can be biased with a positive polarity and other electrodes 542 can be biased with a negative polarity. This embodiment provides a bipolar stimulation to the brain 120. The particular configuration of the electrodes 542 activated during treatment can be optimized after implantation to provide the most efficacious therapy for the patient P.
The particular waveform of the applied stimulus depends upon the symptoms of the patient P. In one embodiment, the stimulus includes a series of biphasic, charge balanced pulses. In one aspect of this embodiment, each phase of the pulse is generally square. In another embodiment, the first phase can include a generally square wave portion representing an increase in current above a reference level, and a decrease below the reference level. The second phase can include a gradual rise back to the reference level. The first phase can have a pulse width ranging from about 25 microseconds to about 400 microseconds. In particular embodiments, the first phase can have a pulse width of 100 microseconds or 250 microseconds. The total pulse width can range up to 500 milliseconds.
The voltage of the stimulus can have a value of from about 0.25 V to about 10.0 V. In further particular embodiments, the voltage can have a value of from about 0.25 V to about 5.0 V, about 0.5 V to about 3.5 V, about 2.0 V to about 3.5 V or about 3 V. The voltage can be selected to be below a level that causes movement, speech or sensation in the patient (e.g., subthreshold) or above such a level (e.g., suprathreshold). In certain embodiments, the practitioner may control the current applied to the patient, in addition to or in lieu of controlling the voltage applied to the patient.
The frequency of the stimulus can have a value of from about 25 Hz to about 250 Hz. In particular embodiments, the frequency can have a value of from about 50 Hz to about 150 Hz, or about 100 Hz. The stimulation can be applied for a period of 0.5 hour-4.0 hours, and in many applications the stimulation can be applied for a period of approximately 0.5 hour-2.0 hours, either during language-based therapy (e.g., language comprehension training) or before, during and/or after such therapy. In other embodiments, the stimulation can be applied continuously, or only during waking periods but not during sleeping periods. It may be particularly effective to treat language disorders by applying stimulation before, during, and/or after language-based therapy because the language centers of the brain may be active during many periods of time in addition to active therapy periods. In particular aspects of this embodiment, the characteristics (e.g., current, voltage, waveform, pulse duration, frequency) are different depending on whether the stimulation is applied before, during or after the language-based therapy. In still further embodiments, the stimulation can be applied while a selected drug (e.g., an amphetamine or other neuroexcitatory agent) is active. In other embodiments, such drugs are not administered. Examples of specific electrical stimulation protocols for use with an electrode array at an epidural stimulation site are as follows:
In one aspect of embodiments of the systems described above with reference to
The support member 741 can be configured to be implanted in the skull 132 or another region of a patient P above the neckline. In one embodiment, for example, the support member 741 includes a housing 744 and an attachment element 745 connected to the housing 741. The housing 744 can be a molded casing formed from a biocompatible material, and can have an interior cavity for carrying the pulse system 751 and a power supply. The housing 744 can alternatively be a biocompatible metal or another suitable material. The housing 744 can have a diameter of approximately 1-4 cm, and in many applications the housing 744 can be 1.5-2.5 cm in diameter. The thickness T of the housing 744 can be approximately 0.5-4 cm, and can more generally be about 1-2 cm. The housing 744 can also have other shapes (e.g., rectilinear, oval, elliptical) and other surface dimensions. The stimulation system 750 can weigh 35 g or less and/or can occupy a volume of 20 cc or less. The attachment element 745 can include a flexible cover, a rigid plate, a contoured cap, or another suitable element for holding the support member 741 relative to the skull 132 or other body part of the patient P. In one embodiment, the attachment element 745 includes a mesh, e.g., a biocompatible polymeric mesh, metal mesh, or other suitable woven material. The attachment element 745 can alternatively be a flexible sheet of Mylar, polyester, or another suitable material.
In one aspect of an embodiment shown in
The embodiment of the stimulation system 750 shown in
The configuration of the stimulation system 750 is not limited to the embodiment shown in
The pulse system 751 shown in
In one aspect of an embodiment shown in
To implant the stimulation apparatus 960, a burr hole 935 is cut completely through the skull 132 of the patient P at a predetermined location identified according to the methods set forth above. The burr hole 935 can also pass through the dura mater (not shown
In one aspect of the embodiments described above with reference to
The information collected while the stimulation system is active can be used to determine whether the stimulation system is creating the desired response in the patient's brain, and/or whether the response is occurring in the desired area of the patient's brain. This technique can be used to provide feedback on the efficacy of the stimulation system and can also be used to adjust aspects of the stimulation system. For example, when the stimulation system includes a plurality of electrodes, the foregoing technique can be used to determine which of the electrodes is providing the desired response. This technique can also be used to determine whether the voltage level (and/or the variation of the voltage level) of the signals applied to the electrodes produces the desired effect. Accordingly, such techniques can be used in addition to or in lieu of receiving direct feedback from the patient to determine the efficacy of the treatment. Such techniques can also be used to tailor the manner in which the treatment is administered.
From the foregoing, it will be appreciated that specific embodiments of the invention have been described herein for purposes of illustration, but that various modifications may be made without deviating from the spirit and scope of the invention. Accordingly, the invention is not limited except as by the appended claims.
The present application relates to and claims priority to pending U.S. Provisional Application No. 60/432,073, entitled “System and Method for Treating Parkinson's Disease and Other Movement Disorders,” filed Dec. 9, 2002, and pending U.S. Provisional Application No. 60/515,309, entitled “Methods for Treating and/or Collecting Information Regarding Neurological Disorders, Including Language Disorders,” filed Oct. 28, 2003, both incorporated herein by reference. The present application also relates to pending U.S. application Ser. No. 10/072,700, filed Feb. 7, 2002, and incorporated herein by reference.
Number | Name | Date | Kind |
---|---|---|---|
2716226 | Jonas | Aug 1955 | A |
2721316 | Shaw | Oct 1955 | A |
3628193 | Collins | Dec 1971 | A |
3650276 | Burghele et al. | Mar 1972 | A |
3850161 | Liss | Nov 1974 | A |
3918461 | Cooper | Nov 1975 | A |
4019518 | Maurer et al. | Apr 1977 | A |
4030509 | Heilman et al. | Jun 1977 | A |
4125116 | Fischell | Nov 1978 | A |
4140133 | Kastrubin et al. | Feb 1979 | A |
4214804 | Little | Jul 1980 | A |
4245645 | Picard et al. | Jan 1981 | A |
4308868 | Jhabvala | Jan 1982 | A |
4328813 | Ray | May 1982 | A |
4340038 | McKean | Jul 1982 | A |
4390023 | Rise | Jun 1983 | A |
4431000 | Butler et al. | Feb 1984 | A |
4474186 | Ledley et al. | Oct 1984 | A |
4541432 | Molina-Negro et al. | Sep 1985 | A |
4542752 | DeHaan et al. | Sep 1985 | A |
4590946 | Loeb | May 1986 | A |
4607639 | Tanagho et al. | Aug 1986 | A |
4646744 | Capel | Mar 1987 | A |
4702254 | Zabara | Oct 1987 | A |
4817634 | Holleman et al. | Apr 1989 | A |
4844075 | Liss et al. | Jul 1989 | A |
4865048 | Eckerson | Sep 1989 | A |
4869255 | Putz | Sep 1989 | A |
4903702 | Putz | Feb 1990 | A |
4969468 | Byers et al. | Nov 1990 | A |
5002053 | Garcia-Rill et al. | Mar 1991 | A |
5024226 | Tan | Jun 1991 | A |
5031618 | Mullett | Jul 1991 | A |
5044368 | Putz | Sep 1991 | A |
5054906 | Lyons | Oct 1991 | A |
5063932 | Dahl et al. | Nov 1991 | A |
5092835 | Schurig et al. | Mar 1992 | A |
5119832 | Xavier | Jun 1992 | A |
5121754 | Mullett | Jun 1992 | A |
5143089 | Alt | Sep 1992 | A |
5169384 | Bosniak et al. | Dec 1992 | A |
5184620 | Cudahy et al. | Feb 1993 | A |
5193540 | Schulman et al. | Mar 1993 | A |
5215086 | Terry, Jr. et al. | Jun 1993 | A |
5215088 | Normann et al. | Jun 1993 | A |
5224491 | Mehra | Jul 1993 | A |
5255678 | Deslauriers et al. | Oct 1993 | A |
5263967 | Lyons | Nov 1993 | A |
5269303 | Wernicke et al. | Dec 1993 | A |
5271417 | Swanson et al. | Dec 1993 | A |
5282468 | Klepinski | Feb 1994 | A |
5299569 | Wernicke et al. | Apr 1994 | A |
5303705 | Nenov | Apr 1994 | A |
5304206 | Baker, Jr. et al. | Apr 1994 | A |
5314458 | Najafi et al. | May 1994 | A |
5358513 | Powell, III et al. | Oct 1994 | A |
5358514 | Schulman et al. | Oct 1994 | A |
5370672 | Fowler et al. | Dec 1994 | A |
5405375 | Ayers et al. | Apr 1995 | A |
5406957 | Tansey | Apr 1995 | A |
5411540 | Edell et al. | May 1995 | A |
5417719 | Hull et al. | May 1995 | A |
5423864 | Ljungstroem | Jun 1995 | A |
5423877 | Mackey | Jun 1995 | A |
5441528 | Chang et al. | Aug 1995 | A |
5458631 | Xavier | Oct 1995 | A |
5464446 | Dreessen et al. | Nov 1995 | A |
5520190 | Benedict et al. | May 1996 | A |
5522864 | Wallace et al. | Jun 1996 | A |
5537512 | Hsia et al. | Jul 1996 | A |
5540734 | Zabara | Jul 1996 | A |
5540736 | Haimovish et al. | Jul 1996 | A |
5549655 | Erickson | Aug 1996 | A |
5562708 | Combs et al. | Oct 1996 | A |
5575813 | Edell | Nov 1996 | A |
5591216 | Testerman et al. | Jan 1997 | A |
5593432 | Crowther et al. | Jan 1997 | A |
5601611 | Fayram et al. | Feb 1997 | A |
5611350 | John | Mar 1997 | A |
5618531 | Cherksey | Apr 1997 | A |
5628317 | Starkebaum et al. | May 1997 | A |
5674251 | Combs et al. | Oct 1997 | A |
5674264 | Carter et al. | Oct 1997 | A |
5676655 | Howard, III et al. | Oct 1997 | A |
5683422 | Rise | Nov 1997 | A |
5702429 | King | Dec 1997 | A |
5707334 | Young | Jan 1998 | A |
5711316 | Elsberry et al. | Jan 1998 | A |
5713922 | King | Feb 1998 | A |
5713923 | Ward et al. | Feb 1998 | A |
5716377 | Rise et al. | Feb 1998 | A |
5722401 | Pietroski et al. | Mar 1998 | A |
5735814 | Elsberry et al. | Apr 1998 | A |
5750376 | Weiss et al. | May 1998 | A |
5752979 | Benabid | May 1998 | A |
5753505 | Luskin | May 1998 | A |
5769778 | Abrams et al. | Jun 1998 | A |
5772591 | Cram | Jun 1998 | A |
5782798 | Rise | Jul 1998 | A |
5782873 | Collins | Jul 1998 | A |
5792186 | Rise | Aug 1998 | A |
5797970 | Pouvreau | Aug 1998 | A |
5814014 | Elsberry et al. | Sep 1998 | A |
5814092 | King | Sep 1998 | A |
5824021 | Rise | Oct 1998 | A |
5824030 | Yang et al. | Oct 1998 | A |
5832932 | Elsberry et al. | Nov 1998 | A |
5833603 | Kovacs et al. | Nov 1998 | A |
5833709 | Rise et al. | Nov 1998 | A |
5843148 | Gijsbers | Dec 1998 | A |
5843150 | Dreessen et al. | Dec 1998 | A |
5846196 | Siekmeyer et al. | Dec 1998 | A |
5865842 | Knuth et al. | Feb 1999 | A |
5871517 | Abrams et al. | Feb 1999 | A |
5885976 | Sandyk | Mar 1999 | A |
5886769 | Zolten | Mar 1999 | A |
5893883 | Torgerson et al. | Apr 1999 | A |
5904916 | Hirsch | May 1999 | A |
5913882 | King | Jun 1999 | A |
5916171 | Mayevsky | Jun 1999 | A |
5925070 | King et al. | Jul 1999 | A |
5928144 | Real | Jul 1999 | A |
5938688 | Schiff | Aug 1999 | A |
5938689 | Fischell et al. | Aug 1999 | A |
5941906 | Barreras et al. | Aug 1999 | A |
5964794 | Bolz et al. | Oct 1999 | A |
5975085 | Rise | Nov 1999 | A |
5978702 | Ward et al. | Nov 1999 | A |
5983140 | Smith et al. | Nov 1999 | A |
6006124 | Fischell et al. | Dec 1999 | A |
6011996 | Gielen et al. | Jan 2000 | A |
6016449 | Fischell et al. | Jan 2000 | A |
6018682 | Rise | Jan 2000 | A |
6021352 | Christopherson et al. | Feb 2000 | A |
6024702 | Iversen | Feb 2000 | A |
6026326 | Bardy | Feb 2000 | A |
6035236 | Jarding et al. | Mar 2000 | A |
6038480 | Hrdlicka et al. | Mar 2000 | A |
6040180 | Johe | Mar 2000 | A |
6042579 | Elsberry et al. | Mar 2000 | A |
6051017 | Loeb et al. | Apr 2000 | A |
6052624 | Mann | Apr 2000 | A |
6055456 | Gerber | Apr 2000 | A |
6057846 | Sever, Jr. | May 2000 | A |
6057847 | Jenkins | May 2000 | A |
6058331 | King | May 2000 | A |
6060048 | Cherksey | May 2000 | A |
6061593 | Fischell et al. | May 2000 | A |
6066163 | John | May 2000 | A |
6094598 | Elsberry et al. | Jul 2000 | A |
6095148 | Shastri et al. | Aug 2000 | A |
6104956 | Naritoku et al. | Aug 2000 | A |
6104960 | Duysens et al. | Aug 2000 | A |
6122548 | Starkebaum et al. | Sep 2000 | A |
6126657 | Edwards et al. | Oct 2000 | A |
6128527 | Howard, III et al. | Oct 2000 | A |
6128537 | Rise | Oct 2000 | A |
6128538 | Fischell et al. | Oct 2000 | A |
6129685 | Howard, III | Oct 2000 | A |
6134474 | Fischell et al. | Oct 2000 | A |
6149612 | Schnapp | Nov 2000 | A |
6152143 | Edwards | Nov 2000 | A |
6161044 | Silverstone | Dec 2000 | A |
6161045 | Fischell et al. | Dec 2000 | A |
6161047 | King et al. | Dec 2000 | A |
6176242 | Rise | Jan 2001 | B1 |
6190893 | Shastri et al. | Feb 2001 | B1 |
6198958 | Ives et al. | Mar 2001 | B1 |
6205360 | Carter et al. | Mar 2001 | B1 |
6205361 | Kuzma et al. | Mar 2001 | B1 |
6210417 | Baudino et al. | Apr 2001 | B1 |
6221908 | Kilgard et al. | Apr 2001 | B1 |
6227203 | Rise et al. | May 2001 | B1 |
6230049 | Fischell et al. | May 2001 | B1 |
6236892 | Feler | May 2001 | B1 |
6246912 | Sluijter et al. | Jun 2001 | B1 |
6251115 | Williams et al. | Jun 2001 | B1 |
6263225 | Howard, III | Jul 2001 | B1 |
6263237 | Rise | Jul 2001 | B1 |
6280462 | Hauser et al. | Aug 2001 | B1 |
6301493 | Marro et al. | Oct 2001 | B1 |
6304787 | Kuzma et al. | Oct 2001 | B1 |
6319241 | King et al. | Nov 2001 | B1 |
6339725 | Naritoku et al. | Jan 2002 | B1 |
6353754 | Fischell et al. | Mar 2002 | B1 |
6354299 | Fischell et al. | Mar 2002 | B1 |
6356786 | Rezai et al. | Mar 2002 | B1 |
6356792 | Errico et al. | Mar 2002 | B1 |
6360122 | Fischell et al. | Mar 2002 | B1 |
6366813 | DiLorenzo | Apr 2002 | B1 |
6375666 | Mische | Apr 2002 | B1 |
6405079 | Ansarinia | Jun 2002 | B1 |
6418344 | Rezai | Jul 2002 | B1 |
6425852 | Epstein et al. | Jul 2002 | B1 |
6427086 | Fischell et al. | Jul 2002 | B1 |
6456886 | Howard, III et al. | Sep 2002 | B1 |
6459936 | Fischell et al. | Oct 2002 | B2 |
6463328 | John | Oct 2002 | B1 |
6464356 | Sabel et al. | Oct 2002 | B1 |
6466822 | Pless | Oct 2002 | B1 |
6473568 | Kashiyama | Oct 2002 | B2 |
6473639 | Fischell et al. | Oct 2002 | B1 |
6480743 | Kirkpatrick et al. | Nov 2002 | B1 |
6484059 | Gielen | Nov 2002 | B2 |
6487450 | Chen | Nov 2002 | B1 |
6497699 | Ludvig et al. | Dec 2002 | B1 |
6499488 | Hunter et al. | Dec 2002 | B1 |
6505075 | Weiner | Jan 2003 | B1 |
6507755 | Gozani et al. | Jan 2003 | B1 |
6529774 | Greene | Mar 2003 | B1 |
6539263 | Schiff et al. | Mar 2003 | B1 |
6549814 | Strutz et al. | Apr 2003 | B1 |
6556868 | Naritoku et al. | Apr 2003 | B2 |
6569654 | Shastri et al. | May 2003 | B2 |
6591138 | Fischell et al. | Jul 2003 | B1 |
6597954 | Pless et al. | Jul 2003 | B1 |
6609030 | Rezai et al. | Aug 2003 | B1 |
6615065 | Barrett et al. | Sep 2003 | B1 |
6622048 | Mann | Sep 2003 | B1 |
6631295 | Rubinstein et al. | Oct 2003 | B2 |
6633780 | Berger | Oct 2003 | B1 |
6647296 | Fischell et al. | Nov 2003 | B2 |
6658299 | Dobelle | Dec 2003 | B1 |
6665562 | Gluckman et al. | Dec 2003 | B2 |
6684105 | Cohen et al. | Jan 2004 | B2 |
6687525 | Llinas | Feb 2004 | B2 |
6690974 | Archer | Feb 2004 | B2 |
6708064 | Rezai | Mar 2004 | B2 |
6725094 | Saberski | Apr 2004 | B2 |
6731978 | Olsen et al. | May 2004 | B2 |
6764498 | Mische | Jul 2004 | B2 |
6782292 | Whitehurst | Aug 2004 | B2 |
6788975 | Whitehurst et al. | Sep 2004 | B1 |
6795737 | Gielen et al. | Sep 2004 | B2 |
6810286 | Donovan et al. | Oct 2004 | B2 |
6839594 | Cohen et al. | Jan 2005 | B2 |
6850802 | Holsheimer et al. | Feb 2005 | B2 |
6873872 | Gluckman et al. | Mar 2005 | B2 |
6892097 | Holsheimer | May 2005 | B2 |
6895280 | Meadows et al. | May 2005 | B2 |
6898464 | Edell et al. | May 2005 | B2 |
6907296 | Doan et al. | Jun 2005 | B1 |
6922590 | Whitehurst | Jul 2005 | B1 |
6934580 | Osorio et al. | Aug 2005 | B1 |
6944497 | Stypulkowski | Sep 2005 | B2 |
6944501 | Pless | Sep 2005 | B1 |
6949081 | Chance | Sep 2005 | B1 |
6959215 | Gliner et al. | Oct 2005 | B2 |
6990377 | Gliner et al. | Jan 2006 | B2 |
7006859 | Osorio et al. | Feb 2006 | B1 |
7010351 | Firlik et al. | Mar 2006 | B2 |
7015816 | Wildman et al. | Mar 2006 | B2 |
7024247 | Gliner et al. | Apr 2006 | B2 |
7050856 | Stypulkowski | May 2006 | B2 |
7065412 | Swoyer | Jun 2006 | B2 |
7107097 | Stern et al. | Sep 2006 | B2 |
7107104 | Keravel et al. | Sep 2006 | B2 |
7146222 | Boling | Dec 2006 | B2 |
7149586 | Greenberg et al. | Dec 2006 | B2 |
7184840 | Stolz et al. | Feb 2007 | B2 |
7187968 | Wolf et al. | Mar 2007 | B2 |
7187977 | Paul, Jr. | Mar 2007 | B2 |
7191018 | Gielen et al. | Mar 2007 | B2 |
7346395 | Lozano et al. | Mar 2008 | B2 |
20020028072 | Kashiyama | Mar 2002 | A1 |
20020087201 | Firlik | Jul 2002 | A1 |
20020091419 | Firlik et al. | Jul 2002 | A1 |
20020099295 | Gil et al. | Jul 2002 | A1 |
20020099412 | Fischell et al. | Jul 2002 | A1 |
20020138101 | Suda et al. | Sep 2002 | A1 |
20020169485 | Pless et al. | Nov 2002 | A1 |
20030074032 | Gliner | Apr 2003 | A1 |
20030078633 | Firlik et al. | Apr 2003 | A1 |
20030088274 | Gliner et al. | May 2003 | A1 |
20030097161 | Firlik et al. | May 2003 | A1 |
20030114886 | Gluckman et al. | Jun 2003 | A1 |
20030125786 | Gliner et al. | Jul 2003 | A1 |
20030130706 | Sheffield et al. | Jul 2003 | A1 |
20030149457 | Tcheng et al. | Aug 2003 | A1 |
20030176901 | May | Sep 2003 | A1 |
20030187490 | Gliner | Oct 2003 | A1 |
20040073270 | Firlik et al. | Apr 2004 | A1 |
20040082847 | McDermott | Apr 2004 | A1 |
20040088024 | Firlik et al. | May 2004 | A1 |
20040092809 | DeCharms | May 2004 | A1 |
20040102828 | Lowry et al. | May 2004 | A1 |
20040111127 | Gliner et al. | Jun 2004 | A1 |
20040131998 | Marom et al. | Jul 2004 | A1 |
20040138550 | Hartlep et al. | Jul 2004 | A1 |
20040158298 | Gliner | Aug 2004 | A1 |
20040176831 | Gliner et al. | Sep 2004 | A1 |
20040181263 | Balzer et al. | Sep 2004 | A1 |
20040236388 | Gielen et al. | Nov 2004 | A1 |
20040249422 | Gliner et al. | Dec 2004 | A1 |
20050004620 | Singhal et al. | Jan 2005 | A1 |
20050015129 | Mische | Jan 2005 | A1 |
20050021104 | DiLorenzo | Jan 2005 | A1 |
20050021105 | Firlik et al. | Jan 2005 | A1 |
20050021106 | Firlik et al. | Jan 2005 | A1 |
20050021107 | Firlik et al. | Jan 2005 | A1 |
20050021118 | Genau et al. | Jan 2005 | A1 |
20050070971 | Fowler et al. | Mar 2005 | A1 |
20050075679 | Gliner et al. | Apr 2005 | A1 |
20050075680 | Lowry et al. | Apr 2005 | A1 |
20050096701 | Donovan et al. | May 2005 | A1 |
20050113882 | Cameron et al. | May 2005 | A1 |
20050119712 | Shafer | Jun 2005 | A1 |
20050154425 | Boveja et al. | Jul 2005 | A1 |
20050154426 | Boveja et al. | Jul 2005 | A1 |
20050182453 | Whitehurst | Aug 2005 | A1 |
20050228451 | Jaax et al. | Oct 2005 | A1 |
20060004422 | De Ridder | Jan 2006 | A1 |
20060004423 | Boveja et al. | Jan 2006 | A1 |
20060015153 | Gliner et al. | Jan 2006 | A1 |
20060095088 | De Ridder | May 2006 | A1 |
20060106430 | Fowler et al. | May 2006 | A1 |
20060106431 | Wyler et al. | May 2006 | A1 |
20060129205 | Boveja et al. | Jun 2006 | A1 |
20060173522 | Osorio | Aug 2006 | A1 |
20060217782 | Boveja et al. | Sep 2006 | A1 |
20060241717 | Whitehurst et al. | Oct 2006 | A1 |
20070032834 | Gliner et al. | Feb 2007 | A1 |
20070055320 | Weinand | Mar 2007 | A1 |
20070060974 | Lozano | Mar 2007 | A1 |
20070088403 | Wyler et al. | Apr 2007 | A1 |
20070088404 | Wyler et al. | Apr 2007 | A1 |
20070100398 | Sloan | May 2007 | A1 |
20070100598 | Zeidman | May 2007 | A1 |
20070179534 | Firlik et al. | Aug 2007 | A1 |
20070179558 | Gliner et al. | Aug 2007 | A1 |
20080045775 | Lozano | Feb 2008 | A1 |
20080139870 | Gliner et al. | Jun 2008 | A1 |
Number | Date | Country |
---|---|---|
19750043 | May 1999 | DE |
0214527 | Mar 1987 | EP |
0319844 | Jun 1989 | EP |
0 998 958 | Oct 2000 | EP |
1145736 | Oct 2001 | EP |
1180056 | Nov 2003 | EP |
WO 8707511 | Dec 1987 | WO |
WO 9407564 | Apr 1994 | WO |
WO 9521591 | Aug 1995 | WO |
WO-9745160 | Dec 1997 | WO |
WO 9806342 | Feb 1998 | WO |
WO 0197906 | Dec 2001 | WO |
WO 0209811 | Feb 2002 | WO |
WO 0236003 | May 2002 | WO |
WO 0238031 | May 2002 | WO |
WO 0238217 | May 2002 | WO |
WO 03082402 | Mar 2003 | WO |
WO 03043690 | May 2003 | WO |
WO-03101532 | Dec 2003 | WO |
Number | Date | Country | |
---|---|---|---|
20050033378 A1 | Feb 2005 | US |
Number | Date | Country | |
---|---|---|---|
60432073 | Dec 2002 | US | |
60515309 | Oct 2003 | US |